A Review of Current and Emerging Clinical Data for 3L mRCC
An expert discusses how efficacy and safety data from trials such as METEOR, TIVO-3, TiNivo-2, and LITESPARK-005 guide third line (3L) renal cell carcinoma (RCC) treatment. Differences in trial populations, evolving long-term trends, and prior immune checkpoint inhibitor (ICI) use impact applicability. CONTACT-03 and TiNivo-2 provide key insights, and real-world data and patient-reported outcomes refine clinical decision-making. Community oncologists should critically assess study limitations and evolving evidence when selecting therapy.
Video content above is prompted by the following:
- Please provide a brief overview of the efficacy and safety data supporting these options, as appropriate (eg, phase 2 Study 205, METEOR, control arm of CONTACT-03, TIVO-3, control arm of TiNivo-2, LITESPARK-005).
- How do the populations of these trials compare?
- What are the trends that have emerged with long-term follow-up?
- What guidance can you offer community oncologists when critically weighing the evidence from studies of these 3L options?
- What are the limitations of applying data from older studies in modern practice (eg, prior ICI)?
- What was learned from the CONTACT-03 and TiNivo-2 studies?
- Are there any patient-reported outcomes from these studies or real-world data that you consider informative to practice?
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
